AdaptHealth (NASDAQ:AHCO) Stock Price Down 14.2% After Earnings Miss

AdaptHealth Corp. (NASDAQ:AHCO) was down 14.2% during trading on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $8.71 and last traded at $8.8310. Approximately 750,405 shares traded hands during trading, a decline of 17% from the average daily volume of 904,195 shares. The stock had previously closed at $10.29.

The company reported ($0.76) EPS for the quarter, missing the consensus estimate of $0.34 by ($1.10). AdaptHealth had a net margin of 2.53% and a return on equity of 4.85%. The firm had revenue of $846.29 million during the quarter, compared to the consensus estimate of $832.51 million. During the same quarter in the previous year, the firm posted $0.34 EPS. The company’s revenue was down 1.2% on a year-over-year basis.

Key Stories Impacting AdaptHealth

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Revenue beat consensus: AdaptHealth reported quarterly revenue of $846.3M, above the $832.5M consensus, showing modest top-line resilience despite year‑over‑year revenue decline. Read More.
• Positive Sentiment: Operational highlights: The company said it set patient‑census records in Sleep Health, Respiratory Health and Wellness at Home, which could support future recurring revenue and retention. Read More.
• Neutral Sentiment: Earnings materials available: The Q4 2025 earnings call transcript and the investor presentation were published (useful for digging into segment trends and management commentary). Read More. • Read More.
• Neutral Sentiment: Short‑interest note appears to be a reporting error: a February report showed “0 shares” and NaN changes — not actionable evidence of a short squeeze or heavy shorting. (Data looks unreliable.)
• Negative Sentiment: Large EPS miss and profitability weakness: Analysts expected roughly $0.34 EPS; coverage and the company reported results that missed estimates and showed a sharp decline from the prior year, weighing on investor confidence. Read More.
• Negative Sentiment: Guidance ambiguity: The company’s FY‑2026 disclosure lacked a clear EPS target (and provided a revenue range roughly in line with street expectations), which likely increased uncertainty around near‑term profitability. Read More.

Wall Street Analyst Weigh In

AHCO has been the subject of a number of recent research reports. Canaccord Genuity Group increased their price objective on shares of AdaptHealth from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Wall Street Zen downgraded AdaptHealth from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Weiss Ratings raised shares of AdaptHealth from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, January 30th. Finally, Zacks Research raised shares of AdaptHealth from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $14.25.

Insider Transactions at AdaptHealth

In other AdaptHealth news, Director David Solomon Williams III sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $9.43, for a total transaction of $47,150.00. Following the completion of the sale, the director directly owned 45,045 shares in the company, valued at $424,774.35. This trade represents a 9.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.55% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in AdaptHealth by 4.4% in the 4th quarter. Vanguard Group Inc. now owns 11,768,599 shares of the company’s stock valued at $117,215,000 after purchasing an additional 491,106 shares during the period. Deerfield Management Company L.P. lifted its position in shares of AdaptHealth by 15.9% during the 3rd quarter. Deerfield Management Company L.P. now owns 11,477,730 shares of the company’s stock valued at $102,726,000 after acquiring an additional 1,572,835 shares during the period. Reinhart Partners LLC. grew its holdings in shares of AdaptHealth by 10.6% during the 4th quarter. Reinhart Partners LLC. now owns 8,100,785 shares of the company’s stock worth $80,684,000 after purchasing an additional 773,727 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of AdaptHealth by 7.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,402,699 shares of the company’s stock worth $63,773,000 after purchasing an additional 420,629 shares during the period. Finally, Geode Capital Management LLC raised its stake in AdaptHealth by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 2,627,306 shares of the company’s stock valued at $26,173,000 after purchasing an additional 19,998 shares in the last quarter. Institutional investors own 82.67% of the company’s stock.

AdaptHealth Stock Performance

The stock’s fifty day moving average price is $10.24 and its two-hundred day moving average price is $9.66. The company has a market cap of $1.20 billion, a P/E ratio of 16.09, a P/E/G ratio of 1.17 and a beta of 1.72. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.86 and a current ratio of 1.08.

AdaptHealth Company Profile

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.